COMPASS Pathways (NASDAQ:CMPS) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Cantor Fitzgerald upgraded shares of COMPASS Pathways (NASDAQ:CMPS - Free Report) to a strong-buy rating in a report released on Tuesday, May 13th,Zacks.com reports. Cantor Fitzgerald also issued estimates for COMPASS Pathways' FY2025 earnings at ($1.91) EPS.

Other equities analysts also recently issued research reports about the stock. Stifel Nicolaus began coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of COMPASS Pathways in a research note on Monday, May 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, Canaccord Genuity Group decreased their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $20.20.

COMPASS Pathways Stock Performance

Shares of NASDAQ:CMPS traded up $0.46 during midday trading on Tuesday, hitting $4.81. The stock had a trading volume of 2,506,066 shares, compared to its average volume of 817,731. COMPASS Pathways has a 1 year low of $2.49 and a 1 year high of $8.54. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average price of $3.37 and a two-hundred day moving average price of $3.93. The company has a market capitalization of $446.78 million, a PE ratio of -2.18 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. As a group, equities analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Cerity Partners LLC purchased a new position in COMPASS Pathways during the first quarter worth approximately $29,000. GAMMA Investing LLC boosted its holdings in COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after acquiring an additional 5,003 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in COMPASS Pathways during the fourth quarter valued at about $41,000. Wealthfront Advisers LLC acquired a new stake in COMPASS Pathways during the fourth quarter worth about $43,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of COMPASS Pathways in the 4th quarter worth about $43,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.